🇺🇸 Carboplatin or Cisplatin in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Death — 3 reports (30%)
- Cholecystitis Acute — 1 report (10%)
- Drug Level Increased — 1 report (10%)
- Liver Function Test Abnormal — 1 report (10%)
- Metastases To Liver — 1 report (10%)
- Pneumonia Fungal — 1 report (10%)
- Product Availability Issue — 1 report (10%)
- Radiation Pneumonitis — 1 report (10%)
Other Oncology approved in United States
Frequently asked questions
Is Carboplatin or Cisplatin approved in United States?
Carboplatin or Cisplatin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Carboplatin or Cisplatin in United States?
Second Hospital of Shanxi Medical University is the originator. The local marketing authorisation holder may differ — check the official source linked above.